source
- Kelun-Biotech reports first-line success of Merck-partnered ADC sacituzumab tirumotecan in ChinaKelun-Biotech announced that its antibody‑drug conjugate sacituzumab tirumotecan, developed in partnership with Merck, achieved its primary efficacy endpoints when used as a first‑line therapy in a…
- J&J shares fall 3% as oncology sales miss forecasts, while AstraZeneca invests $600M in lung cancer drugJohnson & Johnson’s stock slipped about 3% on Wednesday even though the company raised its full‑year sales outlook. In its latest quarterly earnings release the firm said revenue in its innovative…